You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 283 No. 24, June 28, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (210)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Aging/ Geriatrics
 •Rheumatology
 •Osteoporosis
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients

Philip S. Wang, MD, DrPH; Daniel H. Solomon, MD, MPH; Helen Mogun, MS; Jerry Avorn, MD

JAMA. 2000;283:3211-3216.

Context  Recent animal studies have found that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) lipid-lowering drugs (statins) substantially increase bone formation, but whether statin use in humans results in clinically meaningful bone formation or a reduction in the risk of osteoporotic fractures is not known.

Objective  To determine whether the use of statins is associated with reduced hip fracture risk.

Design  Case-control study.

Setting and Patients  A total of 6110 New Jersey residents aged 65 years or older and enrolled in Medicare and either Medicaid or the Pharmacy Assistance for the Aged and Disabled program. Case patients (n=1222) underwent surgical repair of a hip fracture in 1994. Control patients (n=4888) were identified at a ratio of 4:1 and frequency-matched to case patients for age and sex.

Main Outcome Measure  Adjusted odds ratio (OR) of hip fracture by statin use in the 180 days and 3 years prior to the index date (the earliest date of admission for surgery), adjusted for demographic and clinical characteristics and health care utilization.

Results  Use of statins in either the prior 180 days (adjusted OR, 0.50; 95% confidence interval [CI], 0.33-0.76) or prior 3 years (adjusted OR, 0.57; 95% CI, 0.40-0.82) was associated with a significant reduction in the risk of hip fracture, even after controlling for variables such as race, insurance status, psychoactive medications, estrogen and thiazide use, ischemic heart disease, cancer, and diabetes mellitus. No significant relationship was observed between use of nonstatin lipid-lowering agents and hip fracture risk. Clear relationships were observed between the degree of reduction in hip fracture risk and the extent of statin use; there was no evidence of such relationships with nonstatin lipid-lowering agents. After adjusting for extent of statin use in the prior 3 years, current use (on the index date) was associated with a 71% reduction in risk (adjusted OR, 0.29; 95% CI, 0.10-0.81). The relationship between statin use and hip fracture risk persisted after controlling for variables such as the number of medications, the Charlson comorbidity index score, and hospitalization or nursing home stay in the last 180 days, as well as after excluding patients who were in a nursing home prior to their index date or who died in the year after their index date. Use of nonstatin lipid-lowering agents was not observed to be associated with reduction in hip fracture risk in any of these alternative models or analyses.

Conclusions  These findings support an association between statin use by elderly patients and reduction in the risk of hip fracture. Controlled trials are needed to exclude the possibility of unmeasured confounders.


Author Affiliations: Program for the Analysis of Clinical Strategies, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Statin Drugs and the Risk of Fracture
, , , , , , , and
JAMA. ;284():1921-1922.
FULL TEXT  

Association Between Bone Mineral Density and Serum Lipids in Men
, , and
JAMA. ;286():791-792.
FULL TEXT  

RELATED ARTICLES

HMG-CoA Reductase Inhibitors and the Risk of Fractures
, , , , and
JAMA. ;283():3205-3210.
FULL TEXT  

Do Statins Prevent Both Cardiovascular Disease and Fracture?
and
JAMA. ;283():3255-3257.
FULL TEXT  

June 28, 2000
JAMA. ;283():3317-3318.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Prevalence of Perioperative Visual Loss in the United States: A 10-Year Study from 1996 to 2005 of Spinal, Orthopedic, Cardiac, and General Surgery
Shen et al.
Anesth. Analg. 2009;109:1534-1545.
ABSTRACT | FULL TEXT  

Optimizing the Start Time of Statin Therapy for Patients with Diabetes
Denton et al.
Med Decis Making 2009;29:351-367.
ABSTRACT  

Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial
Dore et al.
ANN INTERN MED 2009;150:9-18.
ABSTRACT | FULL TEXT  

Fracture healing in HIV-positive populations
Richardson et al.
J Bone Joint Surg Br 2008;90-B:988-994.
ABSTRACT | FULL TEXT  

Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial
Bone et al.
J. Clin. Endocrinol. Metab. 2007;92:4671-4677.
ABSTRACT | FULL TEXT  

Does delay in surgery after hip fracture lead to worse outcomes? A multicenter survey
Novack et al.
Int J Qual Health Care 2007;19:170-176.
ABSTRACT | FULL TEXT  

Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study
Dennison et al.
QJM 2007;100:297-303.
ABSTRACT | FULL TEXT  

Statin-induced Ras Activation Integrates the Phosphatidylinositol 3-Kinase Signal to Akt and MAPK for Bone Morphogenetic Protein-2 Expression in Osteoblast Differentiation
Ghosh-Choudhury et al.
J. Biol. Chem. 2007;282:4983-4993.
ABSTRACT | FULL TEXT  

Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study
Majumdar et al.
BMJ 2006;333:999-999.
ABSTRACT | FULL TEXT  

Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
Bonovas et al.
JCO 2006;24:4808-4817.
ABSTRACT | FULL TEXT  

Commentary: Statins and fracture risk--unresolved questions.
Meier
Int J Epidemiol 2006;35:1308-1309.
FULL TEXT  

Determinants of the Differences in LDL-Cholesterol After Initiation of Statin Treatment
Caspard et al.
The Annals of Pharmacotherapy 2006;40:21-26.
ABSTRACT | FULL TEXT  

Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies
Bonovas et al.
JCO 2005;23:8606-8612.
ABSTRACT | FULL TEXT  

Statin Use and Fracture Risk: Study of a US Veterans Population
Scranton et al.
Arch Intern Med 2005;165:2007-2012.
ABSTRACT | FULL TEXT  

Paradoxical Effects of Statins on Aortic Valve Myofibroblasts and Osteoblasts: Implications for End-Stage Valvular Heart Disease
Wu et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:592-597.
ABSTRACT | FULL TEXT  

Association between Screening for Osteoporosis and the Incidence of Hip Fracture
Kern et al.
ANN INTERN MED 2005;142:173-181.
ABSTRACT | FULL TEXT  

Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study
Li et al.
Neurology 2004;63:1624-1628.
ABSTRACT | FULL TEXT  

Use of Statins and Fracture: Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials
Bauer et al.
Arch Intern Med 2004;164:146-152.
ABSTRACT | FULL TEXT  

Mineral Exploration: Search for the Mechanism of Vascular Calcification and Beyond: The 2003 Jeffrey M. Hoeg Award Lecture
Demer and Tintut
Arterioscler. Thromb. Vasc. Bio. 2003;23:1739-1743.
ABSTRACT | FULL TEXT  

Long-term statin use and psychological well-being
Young-Xu et al.
J Am Coll Cardiol 2003;42:690-697.
ABSTRACT | FULL TEXT  

Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study
LaCroix et al.
ANN INTERN MED 2003;139:97-104.
ABSTRACT | FULL TEXT  

Hesperidin, a Citrus Flavonoid, Inhibits Bone Loss and Decreases Serum and Hepatic Lipids in Ovariectomized Mice
Chiba et al.
J. Nutr. 2003;133:1892-1897.
ABSTRACT | FULL TEXT  

Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss
Fitzpatrick et al.
Proc. Natl. Acad. Sci. USA 2003;100:6027-6032.
ABSTRACT | FULL TEXT  

Role of Vascular Factors in Osteoporosis
Alagiakrishnan et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2003;58:M362-366.
ABSTRACT | FULL TEXT  

Lipid-lowering agents and the risk of hip fracture in a Medicaid population
Ray et al.
Inj. Prev. 2002;8:276-279.
ABSTRACT | FULL TEXT  

Statin Use and Fracture Risk
Seeger et al.
Arch Intern Med 2002;162:2379-2380.
FULL TEXT  

Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane et al.
J. Clin. Endocrinol. Metab. 2002;87:1451-1458.
ABSTRACT | FULL TEXT  

Statin Use, Bone Mineral Density, and Fracture Risk: Geelong Osteoporosis Study
Pasco et al.
Arch Intern Med 2002;162:537-540.
ABSTRACT | FULL TEXT  

Fractures, calcium, and the modern diet
Hegsted
Am. J. Clin. Nutr. 2001;74:571-573.
ABSTRACT | FULL TEXT  

Boning Up (or Down) on Statins
Demer
Arterioscler. Thromb. Vasc. Bio. 2001;21:1565-1566.
FULL TEXT  

Effect of Statins on Bone Mineral Density and Bone Histomorphometry in Rodents
Maritz et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:1636-1641.
ABSTRACT | FULL TEXT  

Nutraceutical Fatty Acids as Biochemical and Molecular Modulators of Skeletal Biology
Watkins et al.
J. Am. Coll. Nutr. 2001;20:410S-416.
ABSTRACT | FULL TEXT  

Association Between Bone Mineral Density and Serum Lipids in Men
Adami et al.
JAMA 2001;286:791-792.
FULL TEXT  

Statins and Fracture Risk
Meier et al.
JAMA 2001;286:669-670.
FULL TEXT  

Use of Statins and Risk of Fractures
van Staa et al.
JAMA 2001;285:1850-1855.
ABSTRACT | FULL TEXT  

Statins and Fracture Risk
Hennessy and Strom
JAMA 2001;285:1888-1889.
FULL TEXT  

Bone Formation and Inflammation in Cardiac Valves
Mohler et al.
Circulation 2001;103:1522-1528.
ABSTRACT | FULL TEXT  

Anabolic Therapy for Osteoporosis
Rosen and Bilezikian
J. Clin. Endocrinol. Metab. 2001;86:957-964.
ABSTRACT | FULL TEXT  

Statins and bones
Moghadasian and Frohlich
CMAJ 2001;164:803-805.
FULL TEXT  

Role of Lipids in Osteoporosis
Parhami et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:2346-2348.
ABSTRACT | FULL TEXT  

Statin Drugs and the Risk of Fracture
El-Sohemy et al.
JAMA 2000;284:1921-1922.
FULL TEXT  

Statin Use May Decrease Bone Fractures
JWatch General 2000;2000:1-1.
FULL TEXT  

Do Statins Prevent Both Cardiovascular Disease and Fracture?
Cummings and Bauer
JAMA 2000;283:3255-3257.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.